Abstract
Purpose: The purpose of the present study was to evaluate the reliability (internal consistency reliability) and validity (concurrent, convergent, factorial, and known-group validity) of the Brief Perceived Cognitive-Impairment Scale in Korean cancer patients.
Methods: A total of 249 cancer patients from a university hospital (both outpatients and inpatients) in South Korea participated in the data collection from July 2012 to January 2014. The 3 clinical experts and 3 research experts evaluated content validity and the content-validity index was calculated. For internal-consistency reliability, Cronbach"s alpha and item-total correlations were evaluated. For convergent validity, Pearson"s correlations were tested with another validated cognitive impairment scale (The Functional Assessment of Cancer Therapy-Cognitive Function). For concurrent validity, Pearson"s correlations were tested with Functional Assessment of Chronic Illness Therapy-Fatigue. For known-group validity, t-test was performed to evaluate whether the measured cognitive impairment differed the in treatment experience groups. For factorial valdity, factor analysis was performed.
Results: The newly developed measure, the Brief Perceived Cognitive-Impairment Scale, showed high internal consistency, with a Cronbach"s alpha of .92. Item-total correlations ranged from .76 to .81. In the content-validity index, all items were scored at higher than .80 and the scale was scored at higher than .92. The new measure was highly associated with another validated cognitive impairment measure (i.e., r = .93). The new measure showed moderate significant correlations with fatigue, a theoretically associated concept with the cognitive impairment (r = .54, p < .001). Factor analysis confirmed that the scale is unidimensional. The subjects undergoing treatment and the subjects expecting treatment statistically differed in the score of the Brief Perceived Cognitive-Impairment Scale (p < .05).
Conclusion: The findings indicate that the new instrument is valid and reliable, for assessing cancer patients" perceived cognitive dysfunction, particularly in concentration, memory, and executive functions. This instrument will be particularly useful in busy clinical settings and research studies examining multiple symptoms, because of its brevity.
Sigma Membership
Non-member
Type
Poster
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
N/A
Keywords:
Cancer, Cancer Measures, Validation Studies, Cognitive Impairment
Recommended Citation
Kim, Hee-Ju, "Developing a new cognitive impairment measure for Korean cancer patients" (2017). INRC (Congress). 202.
https://www.sigmarepository.org/inrc/2017/posters_2017/202
Conference Name
28th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Dublin, Ireland
Conference Year
2017
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Developing a new cognitive impairment measure for Korean cancer patients
Dublin, Ireland
Purpose: The purpose of the present study was to evaluate the reliability (internal consistency reliability) and validity (concurrent, convergent, factorial, and known-group validity) of the Brief Perceived Cognitive-Impairment Scale in Korean cancer patients.
Methods: A total of 249 cancer patients from a university hospital (both outpatients and inpatients) in South Korea participated in the data collection from July 2012 to January 2014. The 3 clinical experts and 3 research experts evaluated content validity and the content-validity index was calculated. For internal-consistency reliability, Cronbach"s alpha and item-total correlations were evaluated. For convergent validity, Pearson"s correlations were tested with another validated cognitive impairment scale (The Functional Assessment of Cancer Therapy-Cognitive Function). For concurrent validity, Pearson"s correlations were tested with Functional Assessment of Chronic Illness Therapy-Fatigue. For known-group validity, t-test was performed to evaluate whether the measured cognitive impairment differed the in treatment experience groups. For factorial valdity, factor analysis was performed.
Results: The newly developed measure, the Brief Perceived Cognitive-Impairment Scale, showed high internal consistency, with a Cronbach"s alpha of .92. Item-total correlations ranged from .76 to .81. In the content-validity index, all items were scored at higher than .80 and the scale was scored at higher than .92. The new measure was highly associated with another validated cognitive impairment measure (i.e., r = .93). The new measure showed moderate significant correlations with fatigue, a theoretically associated concept with the cognitive impairment (r = .54, p < .001). Factor analysis confirmed that the scale is unidimensional. The subjects undergoing treatment and the subjects expecting treatment statistically differed in the score of the Brief Perceived Cognitive-Impairment Scale (p < .05).
Conclusion: The findings indicate that the new instrument is valid and reliable, for assessing cancer patients" perceived cognitive dysfunction, particularly in concentration, memory, and executive functions. This instrument will be particularly useful in busy clinical settings and research studies examining multiple symptoms, because of its brevity.